Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXDOGK)

Drug Name	PMID27774824-Compound-Figure3Example7 Drug Info
Cross-matching ID	TTD Drug ID DMXDOGK

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Janus kinase 3 (JAK-3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[2]
Ritlecitinib	DMYKNME	Alopecia areata	ED70.2	Approved	[3]
ASP-015K	DMZ1UOI	Psoriasis vulgaris	EA90	Phase 3	[4]
VX-509	DM2U3MX	Rheumatoid arthritis	FA20	Phase 2/3	[5]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[3]
ATI-501	DMTY6OF	Alopecia	ED70	Phase 2	[6]
ATI-502	DM8NODR	Alopecia	ED70	Phase 2	[7]
TD-8236	DMTOMJN	Asthma	CA23	Phase 2	[8]
ALXN2075	DM1BSD8	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[9]
SNA-125	DM8L1GJ	Atopic dermatitis	EA80	Phase 1	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting T-cell-specific kinase (ITK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
JTE-051	DM2LBHN	Plaque psoriasis	EA90.0	Phase 2	[10]
CPI-818	DMMBQ20	T-cell lymphoma	2A90	Phase 1	[11]
Pyrazolo[4,3-c]pyridine derivative 2	DMCDFLQ	N. A.	N. A.	Patented	[1]
BMS-509744	DMGH1LX	Inflammation	1A00-CA43.1	Investigative	[12]
BMS-488516	DM6Y1QF	Inflammation	1A00-CA43.1	Investigative	[12]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Janus kinase 3 (JAK-3)	TTT7PJU	JAK3_HUMAN	Inhibitor	[1]
T-cell-specific kinase (ITK)	TT3C80U	ITK_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
5	Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
6	Clinical pipeline report, company report or official report of Aclaris Therapeutics.
7	ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
8	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
9	The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.
10	Characterisation of a K390R ITK Kinase Dead Transgenic Mouse - Implications for ITK as a Therapeutic Target. PLoS One. 2014; 9(9): e107490.
11	Clinical pipeline report, company report or official report of Corvus Pharmaceuticals.
12	Treatment of depersonalization with serotonin reuptake blockers. J Clin Psychopharmacol. 1990 Jun;10(3):200-3.